ExpreS2ion Biotechnologies (Denmark)
At ExpreS2ion Biotech, we are transforming HER2 cancer immunotherapy with ES2B-C001, a novel vaccine built on our proprietary ExpreS2 platform for the efficient production of high-quality HER2 antigens. By combining these antigens with a virus-like particle (VLP) delivery system, ES2B-C001 effectively engages the immune system to generate a broad and durable antibody response. Targeting all four extracellular domains of the HER2 receptor, it offers superior tumour inhibition and resistance preve
Basic Information
- Category: business
- Website: http://expres2ionbio.com/
Documented Facts
- Email: info@expres2ionbio.com (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about ExpreS2ion Biotechnologies (Denmark).
- Canonical profile: https://brandsource.ai/brands/expres2ion-biotechnologies-denmark
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/expres2ion-biotechnologies-denmark/json-ld
- Citation profile API: https://brandsource.ai/api/brands/expres2ion-biotechnologies-denmark/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
At ExpreS2ion Biotech, we are transforming HER2 cancer immunotherapy with ES2B-C001, a novel vaccine built on our proprietary ExpreS2 platform for the efficient production of high-quality HER2 antigens. By combining these antigens with a virus-like particle (VLP) delivery system, ES2B-C001 effectively engages the immune system to generate a broad and durable antibody response. Targeting all four extracellular domains of the HER2 receptor, it offers superior tumour inhibition and resistance preve
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.